Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 18 and 70 years old;~* Patients with histologic proved metastatic breast cancer, unsuitable to be treated with surgery;~* ECOG (Eastern Cooperative Oncology Group) 0\~1;~* Normal functions with heart, liver,renal and bone marrow:WBC≥3.5×109/L；Hb≥90 g/L；plt≥100×109/L;~* Got ICF (Informed Consent Form) before enrollment;~* Life expectancy more than 12 weeks~Exclusion Criteria:~* Pregnant or breast-feeding women or positive serum pregnancy test;~* Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling;~* Participation in any investigational drug study within 4 weeks preceding treatment start;~* Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer;~* Serious uncontrolled intercurrent infections;~* Poor compliance

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Abraxane and Gemcitabine (Type: EXPERIMENTAL): Abraxane and Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).